Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 443 776 3133

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

7380 Coca Cola Drive, Suite 106, Hanover, United States

NLEBRON3 Jul. 17 at 7:09 PM

$PCSA Why don’t short sellers throw surprise parties? Because they hate it when things go up unexpectedly! 😅📉

0 · Reply

NLEBRON3 Jul. 17 at 7:04 PM

$PCSA Can we at least make the chat entertaining

0 · Reply

TheDrunkTrader69 Jul. 17 at 6:40 PM

$PCSA CEO and other upper management bought in heavy at .80 I think they might know something we dont, just saying

1 · Reply

Bridarunaway Jul. 17 at 6:29 PM

$PCSA the volume is drying everyday ... once the direction is set... they need RS and in the same time they need to hold this strong support line. it been holding for months

0 · Reply

race2zero Jul. 17 at 5:38 PM

$PCSA people seem to be really excited about the meeting

0 · Reply

race2zero Jul. 17 at 5:20 PM

$PCSA

0 · Reply

NLEBRON3 Jul. 17 at 5:05 PM

$PCSA

0 · Reply

race2zero Jul. 17 at 3:49 PM

$PCSA

0 · Reply

NLEBRON3 Jul. 17 at 1:42 PM

$PCSA We need some dam volume!

0 · Reply

TheDrunkTrader69 Jul. 17 at 1:04 PM

$PCSA I never like to say before I do it but i have some liquidity gonna add today on dip. I feel good on this. $$$$$

1 · Reply

Processa Pharmaceuticals Provides Portfolio and Business Update

Jun 17, 2025, 12:26 PM EDT - 4 weeks ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 4 weeks ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 13, 2025, 8:00 AM EDT - 4 weeks ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

May 30, 2025, 9:00 AM EDT - 6 weeks ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 3 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 18, 2025, 8:30 AM EDT - 4 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 5 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 5 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 6 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024, 4:05 PM EDT - 10 months ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 19, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 1 year ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 9, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 1 year ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

Feb 10, 2023, 8:00 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

NLEBRON3 Jul. 17 at 7:09 PM

$PCSA Why don’t short sellers throw surprise parties? Because they hate it when things go up unexpectedly! 😅📉

0 · Reply

NLEBRON3 Jul. 17 at 7:04 PM

$PCSA Can we at least make the chat entertaining

0 · Reply

TheDrunkTrader69 Jul. 17 at 6:40 PM

$PCSA CEO and other upper management bought in heavy at .80 I think they might know something we dont, just saying

1 · Reply

Bridarunaway Jul. 17 at 6:29 PM

$PCSA the volume is drying everyday ... once the direction is set... they need RS and in the same time they need to hold this strong support line. it been holding for months

0 · Reply

race2zero Jul. 17 at 5:38 PM

$PCSA people seem to be really excited about the meeting

0 · Reply

race2zero Jul. 17 at 5:20 PM

$PCSA

0 · Reply

NLEBRON3 Jul. 17 at 5:05 PM

$PCSA

0 · Reply

race2zero Jul. 17 at 3:49 PM

$PCSA

0 · Reply

NLEBRON3 Jul. 17 at 1:42 PM

$PCSA We need some dam volume!

0 · Reply

TheDrunkTrader69 Jul. 17 at 1:04 PM

$PCSA I never like to say before I do it but i have some liquidity gonna add today on dip. I feel good on this. $$$$$

1 · Reply

deerix Jul. 17 at 1:04 PM

$PCSA PCSA is a classic catalyst-rich microcap: Clinical milestone ahead (NGC‑Cap) Big licensing deal in progress (PCS12852) Insider buying signals strong confidence Funding secured If you're playing for a biotech rally into H2 2025, this is one of the cleanest setups out there.

0 · Reply

deerix Jul. 17 at 1:02 PM

$PCSA People will miss out again. Just like what happened at $OPEN and many many other plays. But that's good for everyone reading this here and now

0 · Reply

Stockeye2 Jul. 17 at 8:43 AM

$PCSA

0 · Reply

race2zero Jul. 17 at 4:15 AM

$PCSA

0 · Reply

drader Jul. 17 at 1:13 AM

$PCSA

1 · Reply

Leamelia_luu Jul. 17 at 12:32 AM

$PCSA overnight price $.19.

2 · Reply

Trex28 Jul. 16 at 8:35 PM

$PCSA 2K shares or a few hundred dollars can more the price 2%? Yikes. This thing could be $2/share or 2 cents/share depending on the wave of enthusiasm or dread. Kind of unsettling. Ha ha

0 · Reply

NLEBRON3 Jul. 16 at 7:09 PM

$PCSA I asked Geroge K. Ng for news yesterday and he gave me a whack ass 8-K. Should we ask again?

0 · Reply

Newbiplzdonttakemymoney Jul. 16 at 6:53 PM

$PCSA I’m in 🤣 had to put it on my radar, if it drops under .2 I’ll drop some $$$$

1 · Reply

Trex28 Jul. 16 at 6:51 PM

$PCSA Could this thing have finally found a bottom? Seems the four days of selling has quietly flattened out. Some volume would be interesting. But this thing is contingent on news, so it could be another month.

0 · Reply

race2zero Jul. 16 at 6:44 PM

$PCSA been busy at work today, what have I missed?

2 · Reply

jtsxlr Jul. 16 at 6:31 PM

$PCSA This looks promising, what do yall think? https://finance.yahoo.com/news/processa-pharmaceuticals-inc-pcsa-secures-232640813.html . $NCNA , $LAES , $PLUG , $SONM

2 · Reply

Market Cap	2.44M
Revenue (ttm)	0.00
Net Income (ttm)	-11.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,434,454
Avg Vol	22,009,422
Day's Range	N/A - N/A
Shares Out	11.88M
Stochastic %K	34%
Beta	1.30
Analysts	Sell
Price Target	$2.00